Enthusiast of groundwater & subsurface energy modeling. Interested in history , politics & photography. Fan of Star Wars & Star Trek. China is an evil empire
The first wave at Omaha Beach was a disaster. “Thousands of Americans were spilled onto Omaha Beach. The high ground was won by a handful of men like Taylor who on that day burned with a flame bright beyond common understanding.” https://t.co/Oq4tGZ6HgM
General Omar Bradley called it the most dangerous mission of D-Day. He was not wrong.
At 6:30am on June 6, 1944, 225 Army Rangers approached a 100-foot sheer cliff face on the Normandy coast called Pointe du Hoc.
Their mission: climb it.
The cliff was vertical. The Germans were at the top with full visibility of everyone below. As the Rangers fired grappling hooks upward, the Germans cut the ropes. Shot the men hanging on them. Dropped grenades over the edge onto the climbers beneath.
The Rangers kept climbing.
It took roughly 40 minutes. Men fell. Men were shot off the ropes. The ones behind them grabbed the ropes and kept going.
They reached the top.
Then came the gut punch: the massive 155mm artillery guns they had been sent to destroy were gone. The Germans had moved them inland before the invasion. The entire mission had been sent to destroy guns that weren't there.
Most commanders would have regrouped and called it done.
The Rangers fanned out. Two miles inland, they found the guns, hidden in an orchard, already aimed at Utah Beach and loaded to fire. They destroyed every one with thermite grenades.
Then they dug in. Cut off, with almost no ammunition, no reinforcements, and no resupply, 225 men held Pointe du Hoc against relentless German counterattacks for two full days.
When relief finally arrived, only 90 Rangers could still stand and fight.
Their names are carved on a memorial in Normandy. Most Americans today cannot name a single one.
"The beachhead is secure, but the price was high. Now that it is over it seems to me a pure miracle that we ever took the beach at all.” -Ernie Pyle. To those who liberated people from tyranny, and especially to those who made the ultimate sacrifice, you shall never be forgotten.
🚨Thrilled to share our new @CFR_China report with CFR Global Health's @TomBollyky, @Prof_Yadav_SCM, @OliviaWKosloff, & Elena Every: "The Pharma Choke Point."
The US is dependent on Chinese production for essential medicines, creating a "rare earths" problem in this sector. Seven hundred medicines approved for use in the United States depend on at least one chemical produced solely in China.
For the last year, our study group of pharma and biotech specialists, China scholars, and industrial policy experts came together to:
1⃣ Use commercial data to map the dependencies
2⃣ Devise a typology of three unique "archetypes" of these dependencies
3⃣ Craft solutions to address these dependencies
A few key points follow below:
➡️China's Leverage is real — Beijing doesn't need a wartime crisis to exploit it. It can slow shipments, delay licenses, or reroute flows through "peacetime weaponization." That's the playbook it has already run on rare earths.
➡️Current dependence is structural — It's the product of decades of Chinese state investment and Western pursuit of the low-cost solution. China controls the raw/starting materials for 94% of US amoxicillin, 74% of heparin, and 70% of acetaminophen. It's dominating preclinical work in biotech. And diversifying downstream offers no real protection from upstream dependence.
➡️Archetype 1: Upstream Dependence — Roughly 700 medicines Americans depend on at least one chemical made only in China, including antibiotics, blood thinners, ER drugs. Solutions include:
- building a strategic reserve of critical medicines
- building "allied scale" to create diversified production
- mix various long-term supply and demand interventions to change economic viability for KSMs, APIs, and other upstream inputs (more in the report)
➡️Archetype 2: Competitive Displacement of U.S. Biomanufacturing and Clinical Trial Capacity — For innovative biologics—medicines made from living cells—such as monoclonal antibodies, the risk is not a single upstream choke point but competitive displacement across every stage of the value chain: discovery, clinical development, contract manufacturing, and market access. The U.S. is losing a critical capability: now, WuXi alone handles nearly half of US clients' development programs. China alone is more than half of all late-stage monoclonal antibody programs. Lock-in deepens at every stage. Solutions include:
- accelerating first-in-human clinical trials in the United States
- funding and incentivizing the adoption of advanced biologics manufacturing technologies (e.g., low-cost capital from the USG)
- building contract research alternatives in allied countries like South Korea
- bolstering the U.S. biomanufacturing workforce
- creating a system to secure artificial intelligence (AI)–ready biodata and digital chemistry, manufacturing, and controls.
➡️Archetype 3: Dependence on PRC Infrastructure — Here, the vulnerability is not disruption in the supply of an existing product, but Chinese control over the research-and-development (R&D) infrastructure underlying future pharmaceutical innovation. Growing reliance on China for DNA synthesis is just one example. Solutions include:
- improving DNA supply chain security
- enhancing transparency and disclosing provenance
- increasing federal investment in next-generation DNA synthesis technologies
- and bolstering allied cooperation on standard-setting and procurement to encourage the adoption of these technologies.
➡️Key Takeaway: China has both the tools and demonstrated willingness to weaponize U.S. pharmaceutical dependence: the structural conditions enabling it run through nearly every tier of the pharmaceutical supply. The question is not whether to act, but if the United States will manage to do so before a crisis makes the cost of decades of inaction unavoidable.
I am so grateful to Tom, Prashant, Elena, Olivia, Chloe, Ben, Aarya, CFR's publications team, and so many others who made this possible. It was tremendously educational to work together on this project.
On June 4, the world marks 37 years since the Chinese Communist Party ordered its troops to attack thousands of peaceful demonstrators in and around Tiananmen Square. Those who sacrificed to uphold their unalienable rights of free expression and peaceful assembly will be vindicated someday.
Alongside the ongoing oppression of Muslim and indigenous groups in Xinjiang and Tibet, China has been investing heavily in the economy - building massive energy and transport infrastructure, factories and tourism. Part 2 of our Western China series:
https://t.co/eqWwkiRXbH
The Chinese government has mastered the art of strategic concession:offering just enough flexibility to deflect criticism while leaving its core agenda untouched. The “compromises” were never about changing course, only about managing appearances.
NEW: Xinjiang has the highest detention capacity in the world, according to FT analysis - enough space for almost 1 in 40 people in the region - more than five years after the Chinese govt announced the camps had closed.
NEW: Xinjiang has the highest detention capacity in the world, according to FT analysis - enough space for almost 1 in 40 people in the region - more than five years after the Chinese govt announced the camps had closed.
🚨 New analysis reveals Xinjiang has the highest detention capacity in the world.
Together with cross-party colleagues, IPAC 🇬🇧's @MPIainDS@alexsobel have written to the Foreign Secretary & Special Envoy for Freedom of Religion or Belief to urge action.
https://t.co/hIKW2KUx9E